^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SLC-391
i
Other names: SLC-391, SLC-0211, XZB-0004
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
SignalChem Lifesci, Sihuan Pharmaceutical
Drug class:
AXL inhibitor
Related drugs:
2ms
A Study of XZB-0004 in Patients With Solid Tumors (clinicaltrials.gov)
P1, N=128, Recruiting, Xuanzhu Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
SLC-391
5ms
KEYNOTE-C62: Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers (clinicaltrials.gov)
P1/2, N=92, Recruiting, SignalChem Lifesciences Corporation | Trial completion date: Dec 2027 --> Sep 2028 | Trial primary completion date: Dec 2025 --> Sep 2026
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Keytruda (pembrolizumab) • SLC-391
1year
KEYNOTE-C62: Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers (clinicaltrials.gov)
P1/2, N=98, Recruiting, SignalChem Lifesciences Corporation | Phase classification: P1b/2 --> P1/2
Phase classification
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • PD-L1 overexpression
|
Keytruda (pembrolizumab) • SLC-391
over1year
KEYNOTE-C62: Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers (clinicaltrials.gov)
P1b/2, N=102, Recruiting, SignalChem Lifesciences Corporation | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • PD-L1 overexpression
|
Keytruda (pembrolizumab) • SLC-391
4years
[VIRTUAL] Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment (ASH 2020)
To test whether targeting of the AXL/GAS6 pathway is a feasible treatment strategy for AML, in particular to eradicate LSCs, we developed SLC-391, a novel, potent and selective AXL inhibitor. Importantly, the combination of AXL inhibition plus venetoclax treatment was not toxic to normal BM cells from healthy donors. Hence, our findings identify a promising, improved and specific treatment strategy for AML, particularly patients with high AXL/GAS6 expression.
IO biomarker
|
AXL (AXL Receptor Tyrosine Kinase) • GAS6 (Growth arrest specific 6)
|
GAS6 elevation
|
Venclexta (venetoclax) • SLC-391
Share via
